↓ Skip to main content

Extended Interval Dosing Natalizumab and impact on neuropsychological deficits in Relapsing-Remitting Multiple Sclerosis

Overview of attention for article published in Multiple Sclerosis Journal – Experimental, Translational and Clinical, February 2022
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (66th percentile)
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

news
1 news outlet

Readers on

mendeley
16 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Article details
Title
Extended Interval Dosing Natalizumab and impact on neuropsychological deficits in Relapsing-Remitting Multiple Sclerosis
Published in
Multiple Sclerosis Journal – Experimental, Translational and Clinical, February 2022
DOI 10.1177/20552173211070752
Pubmed ID
Authors

Login to access the Attention Digest and the Sentiment Analysis related to this output.

Timeline Attention over time Attention Score history
Login to access the full charts related to this output.
Activity
Login to access the full charts related to this output.
Mendeley demographics

Mendeley demographics

The data shown below were compiled from readership statistics for 16 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Login to view Mendeley reader trends over time.

Geographical breakdown

Geographical breakdown
Country Count As %
Unknown 16 100%

Demographic breakdown

Readers by professional status
Readers by professional status Count As %
Lecturer 3 19%
Student > Ph. D. Student 2 13%
Other 1 6%
Student > Master 1 6%
Researcher 1 6%
Other 0 0%
Unknown 8 50%
Readers by discipline
Readers by discipline Count As %
Arts and Humanities 1 6%
Nursing and Health Professions 1 6%
Computer Science 1 6%
Medicine and Dentistry 1 6%
Neuroscience 1 6%
Other 2 13%
Unknown 9 56%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 February 2022.
All research outputs
#8,191,642
of 27,658,632 outputs
Outputs from Multiple Sclerosis Journal – Experimental, Translational and Clinical
#168
of 409 outputs
Outputs of similar age
#151,613
of 460,963 outputs
Outputs of similar age from Multiple Sclerosis Journal – Experimental, Translational and Clinical
#6
of 11 outputs
Altmetric has tracked 27,658,632 research outputs across all sources so far. This one has received more attention than most of these and is in the 69th percentile.
So far Altmetric has tracked 409 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.1. This one has gotten more attention than average, scoring higher than 57% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 460,963 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 66% of its contemporaries.
We're also able to compare this research output to 11 others from the same source and published within six weeks on either side of this one. This one is in the 36th percentile – i.e., 36% of its contemporaries scored the same or lower than it.